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ABSTRACT Health-related quality of life or health status is significantly impaired in bronchiectasis.
There is a paucity of brief, simple-to-use, disease-specific health status measures. The aim of this study
was to develop and validate the Bronchiectasis Health Questionnaire (BHQ), a new health status measure
that is brief and generates a single overall score.
Patients with bronchiectasis were recruited from two outpatient clinics, during a clinically stable stage.
The development of the questionnaire followed three phases: item generation and item reduction using
Rasch analysis, validation, and repeatability testing. The BHQ was translated into 11 languages using
standardised methodology.
206 patients with bronchiectasis completed a preliminary 65-item questionnaire. 55 items were removed
due to redundancy or poor fit to the Rasch model. The final version of the BHQ consisted of 10 items.
Internal consistency was good (Cronbach’s α=0.85). Convergent validity of the BHQ with the St George’s
Respiratory Questionnaire was high (r=−0.82; p<0.001) and moderate with lung function (forced
expiratory volume in 1 s % predicted r=−0.27; p=0.001). There was a significant association between BHQ
scores and number of exacerbations of bronchiectasis in the last 12 months (p<0.001), hospital admissions
(p=0.001) and computed tomography scan bronchiectasis pulmonary lobe counts (p<0.001). BHQ scores
were significantly worse in patients with sputum bacterial colonisation versus no colonisation (p=0.048).
The BHQ was highly repeatable after 2 weeks (intraclass correlation coefficient 0.89).
The BHQ is a brief, valid and repeatable, self-completed health status questionnaire for bronchiectasis
that generates a single total score. It can be used in the clinic to assess bronchiectasis from the patient’s
perspective.
This article has supplementary material available from erj.ersjournals.com
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ORIGINAL ARTICLE
BRONCHIECTASIS
Introduction
Bronchiectasis is a persistent or progressive condition that is characterised by dilated and often
thick-walled bronchi [1]. Symptoms of bronchiectasis include breathlessness, cough, sputum production
and haemoptysis. The severity of bronchiectasis can be assessed with physiological, radiological and
composite measures such as the Bronchiectasis Severity Index (BSI) and the FACED score [2, 3]. The
patient’s perception of the condition is also important [4, 5]. Health status or health-related quality of life
is defined as “the perception of the impact of health on an individual’s contentment or satisfaction with
life in areas they consider important” [6]. Health status is significantly impaired in bronchiectasis [7, 8]. It
can be assessed and quantified with validated questionnaires [9, 10]. They can be used to improve
communication between a patient and their clinician, target therapy to specific areas of health, and
evaluate the effectiveness of treatment [11].
A recent systematic review has identified several validated health status questionnaires that can be used in
bronchiectasis, such as the disease-specific Quality of Life-Bronchiectasis (QoL-B), and the
non-disease-specific St George’s Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire
(LCQ) [8, 10, 12–14]. These questionnaires have limitations of being relatively long, do not generate a total
score (QoL-B) and are not disease specific (SGRQ and LCQ) [8]. There has been a trend recently to
develop brief health status tools with simple overall scores, so that they are practical for clinical use [15].
The increasing use of item response theory methodology to develop health status questionnaires has
facilitated briefer tools. One such method uses Rasch analysis, facilitating the creation of unidimensional
scales with interval scaling properties [16]. Examples include CAT (chronic obstructive disease (COPD)
assessment tool) and K-BILD (King’s Brief Interstitial Lung Disease questionnaire) [15, 17]. We set out to
develop and validate a bronchiectasis-specific health status questionnaire. Our aim was to develop a
well-validated tool that was brief and easy to administer and interpret, with a single overall score.
Methods
Phase 1: item generation and participants
Item generation
A preliminary Bronchiectasis Health Questionnaire (BHQ) was developed following: 1) a systematic literature
review of health status questionnaires in bronchiectasis and review of other health status measures [8];
2) face-to-face semistructured interviews with 12 consecutive patients with bronchiectasis; and 3) feedback
from a multidisciplinary team consisting of respiratory physicians, respiratory physiotherapists, a nurse, a
pharmacist and a sociologist. The aim of the interviews was to identify relevant issues and topics to inform
the item generation. The interviews began with open-ended questions and continued with more specific
topics. Examples of open-ended questions were: Can you describe what it is like to have bronchiectasis? How
does it affect your everyday life? The interviews were conducted until saturation (no new items were
emerging) [10]. Patients were asked to complete and comment on a preliminary version of the questionnaire.
The items of the questionnaire referred to the last 14 days and responses were selected from a seven-point
Likert scale. The response scales for items whose high scores represented poor health status were reversed to
ensure high scores represented good health status for consistency of analysis.
Participants
The preliminary BHQ was evaluated in patients with bronchiectasis attributed to various aetiologies,
excluding cystic fibrosis. Consecutive patients were recruited prospectively from secondary care (King’s
College Hospital, London, UK) and tertiary care (Royal Brompton Hospital, London, UK) specialist clinics
from November 2012 to August 2014. Patients reporting an exacerbation of their bronchiectasis in the
previous 2 weeks were excluded. A substudy was conducted in an independent group of consecutive patients
in a specialist bronchiectasis clinic in Guangzhou (Guangdong, China) to assess the clinical properties of a
translated BHQ (patient interviews, internal reliability and construct validity by assessing the relationship
with computed tomography (CT) scan affected pulmonary lobe count). Demographics and clinical
characteristics were recorded. Patients completed the BHQ, SGRQ and visual analogue scales (VASs, 0–
100 mm) for severity of breathlessness (dyspnoea), cough and sputum, independently when attending their
routine clinical appointment. A researcher who was not involved in the clinical care of the patient
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administered the questionnaires. Patients were excluded from the study if they could not read the
questionnaire or completed <85% of the items. The diagnosis of bronchiectasis was the first and main
aetiology, and was based on clinical characteristics and CT scan, consistent with the British Thoracic Society
guidelines [1]. Sputum colonisation status was recorded using the clinical records of the most recent sputum
analyses. Sputum bacteria colonisation was assessed and defined as at least two positive cultures, a minimum
3 months apart and within 1 year [2]. All patients provided written informed consent and the study was
approved by the Research Ethics Committee London – Queen Square (12/LO/1437).
Phase 2: item reduction, Rasch analysis and validation
Item reduction
Items were removed if there was a significant floor effect or ceiling effect response ⩾50% [18]. Items with
missing values ⩾5% were eliminated. The weaker items of highly intercorrelated item pairs (r>0.8) were
removed by face validity [17].
Rasch analysis
Rasch analysis assesses the fit of a questionnaire to a unidimensional model [19]. A questionnaire that fits
the Rasch model has interval scaling properties. Rasch analysis is based on the theory that the response to an
item is governed by two factors: the level of ability of the person and the level of difficulty represented by the
item. Patients are more likely to respond to items of lower difficulty (less severe health status) and less likely
to respond to more difficult items (more severe health status). Rasch analysis was performed for the
development of BHQ and items that did not meet the model were removed. This involved an iterative
statistical process where the item with the poorest fit to the model was removed and the remaining items
retested until a reliable and unidimensional scale was identified. The item–trait interaction was used to assess
the questionnaire fit to a unidimensional model. Items were removed if they did not fit to the model,
indicated by a significant Chi-squared test for the overall item–trait interaction or individual items. The
summation of the difference between the observed and expected scores for all persons, called item fit
residuals ⩽−2.5 or ⩾2.5, indicated items that did not measure the same attribute as the domain being tested
and were also removed. Summary item fit residuals and person fit residuals were item–person interaction
statistics transformed to approximate a z-score; mean±SD residual of ∼0±1 indicated good fit to the model.
The Person Separation Index (PSI) aimed to assess the ability of the BHQ to discriminate patients with
different levels of health status impairment and test the reliability of the fit statistics. Internal consistency was
assessed using Cronbach’s α coefficient. Likert response scale weightings for individual items were combined
if necessary to ensure they detected progressive changes in health status. The BHQ total score was obtained
following logit transformation of raw responses and then transformed to a range of 0–100 (100 indicating
best health status). Differential item functioning (DIF) was evaluated to assess the influence of age, sex,
aetiology of bronchiectasis, forced expiratory volume in 1 s (FEV1) % predicted and colonisation status
(colonisation, no colonisation). The final version for the BHQ was retested with Rasch analysis.
Construct validity
Construct (convergent/divergent) validity, an assessment of an instrument against other standards that
provide an indication of the true value of measurements, was assessed by investigating the relationship
between the final BHQ and lung function, CT scan bronchiectasis pulmonary lobe count, exacerbations,
hospitalisations, sputum bacterial colonisation, symptom scales and other health status questionnaires.
Spirometry was assessed within 6 months of completion of the BHQ. Patients completed the SGRQ, which
is a respiratory-specific health status questionnaire originally developed for patients with COPD and
asthma [14]. The SGRQ has been validated in bronchiectasis and has been the most widely used
questionnaire in this condition [8, 9]. Patients also completed three symptom severity VASs (0–100 mm)
for breathlessness (dyspnoea), sputum and cough (timeframe last 2 weeks) [11]. The BHQ was
administered first, and the SGRQ and VASs were completed in a random order. All measurements were
performed prior to patients seeing the doctor. CT scan bronchiectasis pulmonary lobe counts were
assessed by an experienced pulmonary radiologist blinded to clinical details in an independent group of
patients in Guangzhou. A CT scan was assessed if available within the last 12 months.
Phase 3: repeatability
To investigate the repeatability of the BHQ, a subgroup of unselected, consecutive patients completed the
BHQ on two occasions, 2 weeks apart. Only patients whose condition was considered clinically stable by
both clinician and patient were recruited (patients reporting their condition was unchanged on a global
rating of change scale). Patients were excluded if they had an upper or lower tract respiratory infection or
change of medication within the previous 2 weeks.
https://doi.org/10.1183/13993003.01532-2016 3
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BHQ translations
The BHQ was translated into 11 languages by MAPI Language Services (Lyon, France), specialists in
health status questionnaire translation: nine Indo-European (Dutch for Belgium and the Netherlands,
English for the USA, French for Belgium and France, German, Italian, and Spanish for Spain and the
USA), one Japonic ( Japanese) and one Sino-Tibetan (Mandarin). In each country, the following
translation method (i.e. linguistic validation) was used: 1) in-depth analysis of the original (i.e. concept
definition) and suggestion of suitable translation alternatives; 2) forward/backward translation step (or
adaptation for English and Spanish versions); 3) review of the back translation by the developer; and
4) review of the translated questionnaire by a respiratory clinician fluent in the language. The clinical
properties of a translated BHQ were assessed further in a single centre in China (Mandarin): patient
interviews, internal reliability and construct validity (association with CT scan pulmonary lobe scores).
Analysis
SPSS version 22.0 (SPSS, Chicago, IL, USA), Prism 5 (GraphPad, La Jolla, CA, USA) and RUMM2030
(www.rummlab.com.au) were used for statistical analysis. Mean±SD was used as descriptive statistics for
parametric distributions and median (interquartile range) for nonparametric distributions. Significance
was set as p<0.05. Correlations between parameters were assessed with Pearson’s r and Spearman’s ρ.
Univariate analysis was performed to identify associations between health status and age, sex,
bronchiectasis aetiology and colonisation status. Repeatability of the BHQ was assessed with intraclass
correlation coefficients (ICCs) and a Bland–Altman plot. The 95% limits of agreement were calculated as
1.96SD of within-subject differences. The D’Agostino and Pearson omnibus normality test was used to
assess distribution of data. A minimum completion of eight out of 10 items was necessary to generate a
BHQ score. The average item score (rounded) of the remaining items was used for missing items.
Results
Phase 1: item generation and participant characteristics
12 patients with bronchiectasis (supplementary table E1) were interviewed to identify common themes and
items, and interviews were discontinued when they did not yield new items (supplementary table E2). A
preliminary version of the BHQ consisting of 65 items was developed following the item generation
process (supplementary table E3). The preliminary items covered topics that included respiratory
symptoms, functional capacity, psychological health, medications and treatments, relationships, and social
function. The response scale timeframes were developed from multidisciplinary team discussion. The
preliminary questionnaire was evaluated in four patients with bronchiectasis to assess item wording and
no further changes were made.
The BHQ was administered to 221 patients with bronchiectasis to investigate validity. 15 patients (7.3%)
completed <85% of the questionnaire and were excluded (visually impaired, language difficulty, reasons
not recorded). The remaining patients did not report any difficulty in completing the BHQ. Demographic
and clinical characteristics of the participants are presented in table 1.
Phase 2: item reduction, Rasch analysis and validation
Item reduction and Rasch analysis
The item reduction process is summarised in figure 1. Two items were removed due to missing responses
>5%, 19 items due to a significant floor effect and three items due to a ceiling effect. Three items were
removed because of high item–item correlation. Rasch analysis removed 26 poor-fitting items. There was
no individual item misfit in the remaining items and the item–trait interaction was nonsignificant,
indicating good fit to the Rasch model. The summary statistics for the final 10-item version of the BHQ
indicated a good fit to the model (table 2 and figure 2). The PSI for BHQ total score was 0.85, suggesting
it had good discriminant power to detect differing levels of health impairment. A person–item map
indicated that BHQ items detected health status across a wide spectrum of health status severity
(supplementary figure E1). There was no influence of age, sex, bronchiectasis aetiology, FEV1 % pred and
colonisation status on the response to items (DIF). The response scales for eight items were disordered
and corrected to a progressive scale. The mean±SD BHQ score was not significantly different in patients
with bronchiectasis with coexisting respiratory comorbidities (asthma, COPD, sarcoidosis, pulmonary
fibrosis and lung surgery) (58.3±11.8 versus those with no respiratory comorbidities 60.1±11.8; mean
difference 1.9, 95% CI of difference −1.9–5.6; p=0.323).
Validation
The mean±SD BHQ total score (10 item) was 60.0±11.9. The BHQ correlated strongly with the SGRQ
(all domains and total score) and VAS Dyspnoea, moderately with VAS Cough and VAS Sputum, and
weak–moderately with lung function (table 3). The association between BHQ and SGRQ total score
https://doi.org/10.1183/13993003.01532-2016 4
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TABLE 1 Patient demographics and clinical characteristics
Patients n 206
Age years 59±15
Female % 65
BMI kg·m−2 25±5
Smoking status %
Current 1
Ex 23
Never 76
Bronchiectasis aetiology %
Idiopathic 41
Post-infective 27
Immunodeficiency 11
ABPA 8
Other# 13
Spirometry
FEV1 % pred (range) 75±28 (18.1–150.7)
FVC % pred 91±25
FEV1/FVC 66±14
Sputum colonisation with microorganisms¶ %
Pseudomonas aeruginosa 26
Other 24
None 61
Exacerbations in past 12 months %
0 13
1 12
2 15
3 17
4 11
5 10
>5 22
Hospitalisations in last 12 months %
0 79
1 11
2 4
3 1
4 2
5 1
>5 2
Comorbidities+ %
Asthma 25
Rhinosinusitis 23
Cardiovascular 14
COPD 9
Lung surgery 6
Diabetes mellitus 4
Lung fibrosis/sarcoidosis 3
Malignancy 1
Respiratory symptoms
VAS Dyspnoea 27 (10–53)
VAS Cough 28 (12–53)
VAS Sputum 30 (11–56)
SGRQ
SGRQ Total 43±20
SGRQ Activities 50±27
SGRQ Symptoms 63±21
SGRQ Impact 33±20
Data presented as mean±SD or median (interquartile range), unless otherwise stated. BMI: body mass index;
ABPA: allergic bronchopulmonary aspergillosis; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; COPD: chronic obstructive pulmonary disease; VAS: visual analogue scale; SGRQ: St George’s
Respiratory Questionnaire. #: other aetiologies (total n=27) consist of primary ciliary dyskinesia (n=10),
Kartagener’s syndrome (n=2), inflammatory bowel disease (n=5), rheumatoid arthritis (n=6), Young’s syndrome
(n=3) and yellow nails syndrome (n=1); ¶: sputum colonisation status does not add up to 100% as participants
could be chronically infected with P. aeruginosa and other microorganisms (sputum bacteria colonisation was
assessed and defined as at least two positive cultures, a minimum 3 months apart and within 1 year);
+: comorbidities do not add up to 100% as participants could have no comorbidities or more than one
comorbidities.
https://doi.org/10.1183/13993003.01532-2016 5
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remained unchanged when patients with COPD were excluded (r=−0.826; p<0.001). There were
significant differences in BHQ scores between categories of FEV1 % pred (ANOVA p=0.007) (mean±SD
BHQ score for group FEV1 % pred <50% 55.6±9.5 versus >80% 64.1±11.1; mean difference 8.5, 95% CI of
difference 1.7–15.1; p=0.008) (figure 3). There were no significant differences in BHQ scores between
FEV1 % pred <50% versus 50–80% and >80% versus 50–80% (p>0.05). There were no significant
differences in BHQ scores between sex (p=0.48) or bronchiectasis aetiology (p=0.23). BHQ score did not
correlate with age (r=−0.04; p=0.57). The mean±SD BHQ score was worse in patients with sputum
colonisation (any microorganism) (57.5±10.2 versus no colonisation 61.1±12.7; mean difference 3.6, 95%
CI of difference 0.04–7.20; p=0.048). The mean±SD BHQ score in patients with sputum Pseudomonas
aeruginosa colonisation was 57.4±9.9 versus no colonisation 61.1±12.7 (mean difference 3.7, 95% CI of
difference −0.04–7.4; p=0.053). BHQ scores were significantly associated with exacerbations and
hospitalisation in the last 12 months related to bronchiectasis (table 3, figure 4 and supplementary figure E2).
The mean±SD BHQ score was lower (worse) in patients reporting exacerbations within the last 12 months
(58.8±11.4 versus no exacerbations 68.4±11.6; mean difference 9.6, 95% CI of difference 4.9–14.3; p<0.001)
(figure 4). The mean±SD BHQ score was lower in patients reporting hospital admissions for bronchiectasis
within the last 12 months (54.0±10.9 versus no hospital admission 61.8±11.7; mean difference 7.8, 95% CI
of difference 3.8–11.8; p<0.001) (supplementary figure E2). There was a significant association between
Item generation
Literature 
review
Multidisciplinary 
team
Patient interviews
(n=12)
Correct disordered 
response scales
Differential item
function test
Remove poor-fitting 
items
(n=26)
Rasch analysis
26 items removed
Final 10-item BHQ
Unidimensional scale with total score
Item reduction
Missing 
items
(n=2)
Floor 
effect
(n=19)
Ceiling 
effect
(n=3)
High item–item
correlation
(n=5)
Preliminary questionnaire (65 items)
Completed by 206 patients
FIGURE 1 Summary of the development of the Bronchiectasis Health Questionnaire (BHQ).
TABLE 2 Summary of Rasch analysis
Rasch statistics BHQ total score
Number of items 10
Chi-squared fit statistic 28.16
Degrees of freedom 20
p-value 0.11
Item fit residual (mean±SD) 0.01±1.11
Person fit residual (mean±SD) −0.25±1.11
PSI 0.85
Cronbach’s α 0.85
BHQ: Bronchiectasis Health Questionnaire; PSI: Person Separation Index. The Chi-squared statistic
assesses item–trait interaction; nonsignificance indicates a good fit to the Rasch model (p>0.05). The mean
person and item fit residuals are item–person interaction statistics that are z-transformed; a good fit to the
Rasch model is when they approximate to a mean±SD of 0±1. The PSI assesses how well BHQ discriminates
subjects with differing levels of health status. Cronbach’s α coefficient is a measure of internal reliability.
A PSI and Cronbach’s α coefficient ⩾0.7 is considered acceptable.
https://doi.org/10.1183/13993003.01532-2016 6
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BHQ scores and CT scan bronchiectasis pulmonary lobe count in the substudy group of patients (n=56,
supplementary table E4) (ρ=−0.478; p<0.001).
Phase 3: Repeatability
Repeatability was investigated in 32 patients. ICCs were consistent with good repeatability (ICC 0.89, 95%
CI 0.77–0.94; p<0.01). A Bland–Altman plot of BHQ score repeatability is shown in figure 5.
Translation
The translation process did not reveal any cultural issues as most of the concepts assessed were
cross-culturally relevant. The main difficulties consisted in finding conceptual equivalents to the response
choices designed as Likert-type scales in seven points (e.g. “All of the time” to “None of the time”). In all
countries, translators ensured that the continuity of time was kept between all versions using either
adverbs or synonyms (e.g. “Always” for “All of the time”). Items 2, 4 and 10 raised most discussion across
languages for idiomatic or syntactic reasons. Solutions were found in order to respect the structure and
The Bronchiectasis Health Questionnaire (BHQ)© 2014
This questionnaire is designed to assess how bronchiectasis affects your life. Please read each question carefully and answer by SELECTING the response that best 
applies to you. It is important that you answer all questions as honestly as you can.
1. In the last 14 days, I have been tired.
1. All of the time 2. Most of the time 3. A good bit of the time 4. Some of the time 5. A little of the time 6. Hardly any of the time 7. None of the time
2. In the last 14 days, I have been much slower at doing things than other people of my age.
1. All of the time 2. Most of the time 3. A good bit of the time 4. Some of the time 5. A little of the time 6. Hardly any of the time 7. None of the time
3. In the last 14 days, I have felt anxious.
1. All of the time 2. Most of the time 3. A good bit of the time 4. Some of the time 5. A little of the time 6. Hardly any of the time 7. None of the time
4. In the last 14 days, my chest has felt clear.
1. All of the time 2. Most of the time 3. A good bit of the time 4. Some of the time 5. A little of the time 6. Hardly any of the time 7. None of the time
5. In the last 14 days, I have been embarassed because of my phlegm (sputum).
1. All of the time 2. Most of the time 3. A good bit of the time 4. Some of the time 5. A little of the time 6. Hardly any of the time 7. None of the time
6. In the last 14 days, I have felt short of breath.
1. All of the time 2. Most of the time 3. A good bit of the time 4. Some of the time 5. A little of the time 6. Hardly any of the time 7. None of the time
7. In the last 14 days, my sleep has been disrupted because of my bronchiectasis.
1. Every night 2. Most nights 3. Several nights 4. Some nights 5. Occasionally 6. Rarely 7. Never
8. In the last 14 days, I have had coughing fits.
1. Every day 2. Most days 3. Several days 4. Some days 5. Occasionally 6. Rarely 7. Never
9. In the last 14 days, my phlegm (sputum) contained blood.
1. Every time 2. Most times 3. Several times 4. Sometimes 5. Occasionally 6. Rarely 7. Never
10. In the last 12 months, I have taken antibiotic treatments for a chest infection.
Thank you for completing this questionnaire!
1. More than five times 2. Five times 3. Four times 4. Three times 5. Twice 6. Once 7. None
FIGURE 2 The Bronchiectasis Health Questionnaire (BHQ).
TABLE 3 The relationship between the Bronchiectasis Health Questionnaire (BHQ) and clinical
measures#
BHQ correlation coefficient p-value
FEV1 % pred 0.266 0.001
FVC % pred 0.252 0.003
Exacerbations in last 12 months¶ −0.486 <0.001
Hospitalisations in last 12 months¶ −0.328 0.001
SGRQ Total −0.819 <0.001
SGRQ Activities −0.704 <0.001
SGRQ Symptoms −0.710 <0.001
SGRQ Impact −0.779 <0.001
VAS Dyspnoea+ −0.703 <0.001
VAS Cough+ −0.613 <0.001
VAS Sputum+ −0.481 <0.001
Data are presented as Pearson’s r unless, otherwise stated. FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; SGRQ: St George’s Respiratory Questionnaire; VAS: visual analogue scale.
#: n=206 patients; ¶: exacerbations and hospitalisations related to bronchiectasis; +: Spearman’s ρ. All
p-values <0.01.
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common use of each target language. The clinicians’ review proved useful to clarify the concept of “clear
chest” in question 4, i.e. meaning “chest clear of sputum or congestion”, and led to changes in wording.
There were only minor changes to the wording of the Chinese BHQ following patient interviews.
Cronbach’s α coefficient for the Chinese BHQ (internal reliability) was 0.78, comparable to the original
BHQ. See supplementary Appendix 2 for copies of all translated BHQs.
Discussion
The BHQ is a health status questionnaire developed and validated specifically for patients with
bronchiectasis. The questionnaire items were selected using item response theory to create a unidimensional
scale with interval scaling properties. The BHQ is brief, containing just 10 items, and generates a single
overall health status score. It is simple to administer and most patients found it easy to complete.
The BHQ items were generated following detailed patient interviews exploring the impact of their lung
condition on their health. The preliminary BHQ was assessed using a systematic statistical approach with
Rasch analysis, commonly used in the development of health status tools. Items that did not conform to a
unidimensional scale were eliminated. Redundant items were also removed, if possible, while retaining
essential questionnaire measurement characteristics. Rasch analysis confirmed that the BHQ had good
internal scaling of items and was unidimensional. Unidimensional scales are an important attribute of
health status questionnaires because they confirm that the instrument measures the intended construct,
and allow health status to be quantified as a single number to facilitate clinical utility and interpretation.
The convergent validity of the BHQ (association with the SGRQ) was good, suggesting that the removal of
redundant items did not compromise the BHQ’s ability to measure health status. The BHQ also correlated
well with VASs for breathlessness (dyspnoea), and moderately for cough and sputum scales. The internal
consistency of the BHQ was good and above the recommended threshold for health status questionnaires [20].
The BHQ scores were worse in patients with frequent exacerbations and hospital admissions in the last
12 months due to their bronchiectasis, and also in those with more extensive disease on CT scan and
FIGURE 3 Mean±SD Bronchiectasis
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sputum colonisation with microorganisms. The BHQ was highly repeatable over 2 weeks, but further
studies are needed to determine this over a longer duration.
The association between health status and lung function (FEV1), although statistically significant, was weak.
This is not surprising because health status and measures of lung physiology are very different domains of
health. This weak relationship is similar to that reported in other chronic respiratory disorders, such as
COPD [21]. A weak association with FEV1 has also been reported for the QoL-B questionnaire [7, 10]. Our
findings suggest that health status questionnaires assess a unique aspect of disease severity not captured by
objective measures.
The QoL-B is the only other bronchiectasis-specific health status questionnaire that has recently been
published and validated [7, 10]. The QoL-B comprises 37 items and the scores are presented as eight distinct
domains. There are several differences between the QoL-B and the BHQ. The QoL-B is a considerably longer
questionnaire and does not provide an overall health status score. The BHQ may therefore be more suitable
for clinical and research settings where a brief questionnaire is an important practical consideration, and
when a single score is desirable for ease of clinical interpretation, such as evaluating the response to
therapeutic interventions. In contrast, the QoL-B may be more advantageous when in-depth analysis of
health status is required and when there is a need to identify impairment in specific health domains. The
questionnaires differ in the methodology used to eliminate items from the preliminary questionnaire to
generate the final version. For the QoL-B, item reduction was based on subjective methodology. This may
have retained items clinicians and patients consider important, but it is a method that does not select items
on their scaling properties. In contrast, the BHQ used Rasch analysis to eliminate items systematically. The
validity reported for both questionnaires, such as convergent validity (correlation coefficient with SGRQ:
QoL-B −0.38–−0.85 versus BHQ −0.82), internal consistency (Cronbach’s α: QoL-B 0.66–0.94 versus BHQ
0.85) and repeatability (ICC: QoL-B 0.67–0.88 versus BHQ 0.89) is generally comparable [7, 8, 10, 22]. This
suggests that the removal of redundant items to create a very brief tool has not compromised the
measurement characteristics of the BHQ. There were some differences in the patient populations in which
both questionnaires were validated. The BHQ was validated in an unselected population with bronchiectasis.
The QoL-B was validated in clinical trials that selected participants who had cultured Gram-negative sputum
organisms [7, 10, 22]. We were unable to compare the performance of the BHQ against the QoL-B as it was
not available at the time of this study. Future studies comparing the performance of the BHQ, SGRQ and
QoL-B questionnaires are needed to address this limitation, particularly longitudinal assessment, treatment
responsiveness and association with disease severity tools such as the BSI.
The SGRQ and LCQ are two other health status questionnaires widely used in the assessment of
bronchiectasis [8, 9, 23]. Although they were developed for use in other chronic respiratory conditions, they
have been well validated in patients with bronchiectasis. The internal reliability, construct validity and
repeatability of the BHQ is comparable to that of the SGRQ and the LCQ [8, 9, 24]. The SGRQ is a
considerably longer, comprising of 50 items, and has a greater focus on breathlessness [14]. The LCQ also has
a greater number of items (n=19) and its main focus is on health status related to cough [13]. There is overlap
in the content of five items between the LCQ and BHQ. The BHQ, however, focuses specifically on symptoms
of bronchiectasis, and both breathlessness and cough are represented. A comparative study of the BHQ and
LCQ is needed to determine if assessment of health status with the BHQ covers the domains of the LCQ.
We have translated the BHQ into 11 other languages using standardised methodology. The translations
were conducted by experts (MAPI Language Services) who are experienced in adapting health status
FIGURE 5 Bland–Altman plot (mean
±1.96SD) of repeatability of the
Bronchiectasis Health Questionnaire
(BHQ).
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questionnaires for use in a wide range of countries. We also sought the input of pulmonary clinicians
familiar with bronchiectasis who were literate in these languages. Our translation methodology should be
considered the first step in the cultural adaptation of the BHQ. Further independent evaluation of the
translated BHQ is necessary to obtain the feedback of patients and also determine its validity, such as the
internal consistency. We did assess the validity of the Chinese language BHQ with patient interviews and
assessment of construct validity and internal reliability; this was consistent with the original English
language BHQ. The publication of a health status questionnaire from the outset in multiple languages may
be advantageous in ensuring the standardisation and the quality of the translation (see supplementary
Appendix 2 for copies of the translated BHQ in French, Dutch, German, Italian, Spanish, Japanese,
Chinese (simplified Mandarin), Belgian (French and Dutch), US Spanish and US English).
There are some limitations with health status questionnaire development methodology. We used Rasch
analysis to eliminate items that did not fit a unidimensional model. We eliminated items that were
infrequent, redundant or contributed weakly to health status assessment, or did not conform to optimal
scaling properties. We may have eliminated items important to patients that may have been retained using
methodology based on clinical importance [25]. Our aim was to develop a brief questionnaire that could
quantify health status with the least number of items, while retaining validity, so that it was practical
for clinical use. Health status questionnaires are not a substitute for identifying health-related issues
obtained from a detailed history. The prevalence of idiopathic bronchiectasis in our study was high at
41%. While this may reflect difficultly in identifying causes, the prevalence was similar to 44% reported in
a recent systematic review of 8608 patients [26]. There are a number of well-validated tools now available
to assess the severity of bronchiectasis, such as the BSI and FACED tools [2, 3]. We were unable to
retrospectively assess these scores because some of the clinical components of these scores were not
available or were significantly out of date. We did not assess the extent of bronchiectasis as the duration
between CT scan and study assessments was considerable for many patients. The BSI and FACED tools
assess disease severity, which is distinct from health status measures. We did, however, find a significant
association between the BHQ and FEV1 and breathlessness, components of both severity tools. To our
knowledge, the association between QoL-B and BSI or FACED scores has also not been reported.
Further studies should investigate the relationship between the BSI and FACED and health status assessed
with the BHQ.
The responsiveness and the minimal clinically important difference (MCID) of the BHQ have not been
studied and this needs investigation [27]. The MCID is essential for clinical interpretation of BHQ scores
and therefore the BHQ is likely to be limited to a research tool until this is defined. The high PSI for the
BHQ was, however, consistent with ability to discriminate differing levels of health status. The sample size of
patients (n=12) interviewed was small and it is possible some themes relevant to patients were missed. The
sample was small as the interviews were in depth and it was similar to the development of other health status
tools such as the LCQ. We were able to generate a large preliminary BHQ questionnaire comprising 65 items
that covered a broad range of health domains. It is possible that the presence of comorbidities, such as
asthma, COPD, Aspergillus colonisation and immunoglobulin deficiency, may have impacted the assessment
of health status. The BHQ items, however, were worded specifically to relate to the patient’s bronchiectasis.
The patients were recruited from bronchiectasis clinics and bronchiectasis was the primary diagnosis. Our
patients had mild physiological impairment and it is possible this may have had an impact on the
development of the BHQ. The recruitment of a large sample size (n=206), patients with a wide range of
physiological impairment (lowest FEV1 % pred 18%) and the lack of DIF with FEV1 suggests this is unlikely.
We did not assess the relationship between BHQ scores and the presence of clinically significant
nontuberculous mycobacteria; this should be assessed in future. A potential disadvantage of the BHQ is that
it does not quantify health status in specific health domains, such as psychological, activity and social. We
did, however, set out to develop a very brief and practical health status questionnaire with a single overall
score. A detailed assessment of health domains can be achieved with other questionnaires. The purpose of
question 10 (number of antibiotics taken for chest or respiratory infections in 12 months) was to capture the
impact of frequent respiratory infections on health status. Question 10 may be less responsive when repeated
over a shorter time interval. The BHQ does have nine other items that assess over a short interval; hence, the
impact of one item is likely to be limited. Patients taking long-term antibiotics may have difficulty in
answering question 10. We did not encounter any issues during patient interviews or administration of the
questionnaire in a large number of patients; they were able to relate this item to acute infections. The BHQ
has been evaluated in only three centres and therefore an external validation, including more overseas
centres, is essential in future studies, given the heterogeneous nature of bronchiectasis.
The BHQ has a number of potential applications. It is a quick and valid tool to identify health status
issues important to patients in the clinic. It can be used to help formulate shared care plans between the
patient and the physician. In summary, the BHQ is brief, easy to administer and well validated.
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